Evidence map›Paper›PMID 32140274›Full record

ArticleJournal of breast cancer2020

Acute Lymphoblastic Leukemia in a Patient Treated with Letrozole and Palbociclib.

Jin Hyun Park, Hyunkyung Park, Ki Hwan Kim, Jin-Soo Kim, In Sil Choi, Eun Youn Roh, Ji Eun Kim, Mee Soo Chang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Development of acute myeloid leukemia (AML) in two breast cancer patients undergoing treatment with long-term palbociclib: a dual case report.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jin Hyun ParkDivision of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0003-1078-4139
Hyunkyung ParkDivision of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-5646-8054
Ki Hwan KimDivision of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-9001-6537
Jin-Soo KimDivision of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0003-2636-2352
In Sil ChoiDivision of Hematology-Medical Oncology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-8494-584X
Eun Youn RohDepartment of Laboratory Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-1787-7509
Ji Eun KimDepartment of Pathology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-2156-9875
Mee Soo ChangDepartment of Pathology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.ORCID 0000-0002-0948-799X
Seoul Metropolitan Government · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palbociclib, in conjunction with endocrine therapy, has been approved for the treatment of patients with advanced breast cancer. The common hematological toxicities associated with palbociclib are leukopenia and neutropenia. However, hematological malignancies have not been reported for palbociclib treatment. Here, for the first time, we present a case of acute lymphoblastic leukemia that was diagnosed in a patient undergoing treatment with letrozole and palbociclib for metastatic breast cancer. This case emphasizes the need for long term follow up of patients treated with palbociclib.

Indexed as

Adverse effectsBreast neoplasmsHematologic neoplasmsPalbociclibPrecursor cell lymphoblastic leukemia-lymphoma

Identifiers

PMID32140274
PMCPMC7043942
OpenAlexW2986665338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.